IMDX Stock Summary and Trading Ideas (Insight Molecular Diagnostics | NASDAQ:IMDX)

Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx.

Insight Molecular Diagnostics trades on the NASDAQ stock market under the symbol IMDX.

As of December 4, 2025, IMDX stock price climbed to $5.58 with 23,702 million shares trading.

IMDX has a beta of 0.50, meaning it tends to be less sensitive to market movements. IMDX has a correlation of 0.00 to the broad based SPY ETF.

IMDX has a market cap of $159.95 million. This is considered a Micro Cap stock.

Last quarter Insight Molecular Diagnostics reported $139,000 in Revenue and -$.34 earnings per share. This fell short of revenue expectation by $-146,000 and missed earnings estimates by -$.10.

The top ETF exchange traded funds that IMDX belongs to (by Net Assets): VXF, VTI, IWC.

IMDX support price is $4.99 and resistance is $5.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that IMDX shares will trade within this expected range on the day.